Where Valeant, and Corporate America, Went Wrong
Image: The big political story this week was the Republican presidential debate, and candidates’ usual complaints that too many Americans are falling behind economically. The big corporate governance story, meanwhile, has been the unraveling of Valeant Pharmaceuticals. The two are tied, Compliance Week editor Matt Kelly writes—since Valeant’s misplaced corporate ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
Valeant’s financial restatement begs compliance questions
Valeant Pharmaceuticals’ announced financial restatement raises questions about the drug company’s compliance program and its business model. But it might also serve as an early warning to all publicly listed U.S. companies about the increased room for misjudging the booking of sales once FASB rolls out its new revenue recognition ...
-
OpinionWhy “just do the work” fails in regulated organizations
Most organizational failures are not failures of effort, discipline, or follow-through. They are interpretation failures misdiagnosed as execution problems.
-
News BriefCOSO withdraws draft corporate governance framework due to “shifting” regulations
The Committee of Sponsoring Organizations of the Treadway Commission (COSO) has withdrawn its draft corporate governance framework that it released in May, after “extensive feedback” and provisions in the recently passed “One Big Beautiful Bill” caused its authors to reconsider it.